The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.
The Cytogenesis and Pathogenesis of Pituitary Adenomas*
Abstract
PITUITARY tumors are common neoplasms that exhibit a wide range of biological behavior, in terms of hormonal and proliferative activities. Their hormonal activity is usually reflective of their cytodifferentiation. The adenohypophysis is a complex gland composed of several cell types that are responsible for the production of many hormones. It was once believed that one cell could make only one hormone (1); the concept of plurihormonality in pituitary adenomas was once controversial and poorly understood. However, advances in our recognition of the factors that regulate cell differentiation in the adenohypophysis have led to a new classification of adenohypophysial cell types (2) and a more sophisticated understanding of the mechanisms that determine the patterns of hormone production in pituitary adenomas. For many years there has been controversy regarding the basis of pituitary tumorigenesis. Two prevailing theories have pitted hormonal stimulation against an intrinsic pituitary defect. Several animal models have provided support for the role of hormonal stimulation in the development of these neoplasms, and there is evidence for adenohypophysial production of hypothalamic hypophysiotropic hormones that may be responsible for excess stimulation. Other growth factors have also been shown to cause pituitary tumors. In contrast, the clonal nature of pituitary adenomas and the lack of associated hyperplasia in most patients with pituitary adenomas argue for a molecular defect as the etiology of these lesions. An integrated approach reconciles the two proposed theories of tumorigenesis by applying the multistep theory of carcinogenesis. It is likely that the majority of pituitary adenomas develop from transformed cells that are, nevertheless, dependent on hormonal and/or growth factor stimulation for tumor progression, which will be discussed below.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–222 of 222
Growth hormone-releasing hormone transcripts in human pituitary adenomas.
Levy, A., & Lightman, S. L. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.74.6.1350590 · Cited by 49
Persistence of immunoreactive TRH and GnRH in long-term primary anterior pituitary cultures
May, V., Wilber, J. F., U'Prichard, D. C., et al. (1987) · Peptides · doi:10.1016/0196-9781(87)90022-2 · Cited by 49
The mitogenic effects of corticotrophin-releasing factor on the anterior pituitary gland of the rat
McNicol, A. M., Kubba, M. A. G., & McTeague, E. (1988) · Journal of Endocrinology · doi:10.1677/joe.0.1180237 · Cited by 49
Ikeda, H., Mitsuhashi, T., Kubota, K., et al. (1984) · Endocrinology · doi:10.1210/endo-115-2-556 · Cited by 49
Coire, C. I., Horváth, É., Kovács, K., Smyth, H. S., & Ezzat, S. (1997) · Endocrine Pathology · doi:10.1007/bf02739709 · Cited by 44
Self-citationSuda, T., Tozawa, F., Dobashi, I., HORIBA, N., Ohmori, N., Yamakado, M., Yamada, M., & Demura, H. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116898 · Cited by 43
Miller, G. M., Alexander, J. M., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550798 · Cited by 40
Decreased follistatin gene expression in gonadotroph adenomas
Penabad, J. L., BASHEY, H. M., Asa, S. L., Haddad, G., Davis, K. D., Herbst, A., Gennarelli, T. A., Kaiser, U. B., Chin, W. W., & Snyder, P. J. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.9.8784103 · Cited by 38
Self-citationSTUDIES OF TWO THYROTROPHIN‐SECRETING PITUITARY ADENOMAS: EVIDENCE FOR DOPAMINE RECEPTOR DEFICIENCY
Bevan, J. S., Burke, C. W., Esiri, M. M., Adams, C. B. T., Ballabio, M., NISSIM, M., & Faglia, G. (1989) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1989.tb00454.x · Cited by 37
Human and murine PTX1/Ptx1 gene maps to the region for Treacher Collins Syndrome
Crawford, M. J., Lanctôt, C., Tremblay, J., Jenkins, N. A., Gilbert, D. J., Copeland, N. G., Beatty, B., & Drouin, J. (1997) · Mammalian Genome · doi:10.1007/s003359900589 · Cited by 37
Suda, T., Tozawa, F., Yamada, M., USHIYAMA, T., Tomori, N., Sumitomo, T., NAKAGAMI, Y., Demura, H., & SHIZUME, K. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113557 · Cited by 35
V3 Vasopressin Receptor and Corticotropic Phenotype in Pituitary and Nonpituitary Tumors
de Keyzer, Y., René, P., Lenne, F., Auzan, C., Clauser, É., & BERTAGNA, X. Y. (2008) · Hormone Research · doi:10.1159/000185473 · Cited by 35
Asa, S. L., Kovács, K., Hammer, G. D., Liu, B., Roos, B. A., & Low, M. J. (1992) · Endocrinology · doi:10.1210/endo.131.2.1322279 · Cited by 35
Self-citationSanno, N. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.6.1974 · Cited by 32
Medical Treatment of Cushing Disease
Fleseriu, M. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.10.006 · Cited by 29
Evidence for a nonprolactin, non-growth-hormone mammary mitogen in the human pituitary gland.
Newman, C. B., Cosby, H., Friesen, H. G., Feldman, M. L., Cooper, P., Crescito, V. D., Pilon, M., & Kleinberg, D. L. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.22.8110 · Cited by 28
Pituitary Adenomas: Screening for Gαq Mutations
Oyesiku, N. M., Evans, C.-O., Brown, M. R., Blevins, L. S., Tindall, G. T., & Parks, J. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4436 · Cited by 27
Diagnosis and management of prolactinomas
Wallach, E. E., & Blackwell, R. E. (1985) · Fertility and Sterility · doi:10.1016/s0015-0282(16)48310-x · Cited by 26
In vitro Secretion of ACTH, β-Endorphin and β-Lipotropin in Cushing’s Disease and Nelson’s Syndrome
decke, D. K. L. U., Westphal, M., Schabet, M., & llt, V. H. O. (2008) · Hormone Research · doi:10.1159/000179294 · Cited by 25
Yamada, M., Hashimoto, K., Satoh, T., Shibusawa, N., Kohga, H., Ozawa, Y., Yamada, S., & Mori, M. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.12.4224 · Cited by 23
Human Pituitary Tissue Secretes a Potent Growth Factor for Chondrocyte Proliferation*
KASPER, S., & Friesen, H. G. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-1-70 · Cited by 20
Jackson, S. M., Barnhart, K. M., Mellon, P. L., Gutierrez‐Hartmann, A., & Hoeffler, J. P. (1993) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(93)90107-u · Cited by 13
Cited by
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Dopamine as a Prolactin (PRL) Inhibitor
Ben-Jonathan, N., & Hnasko, R. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.6.0451 · Cited by 983
“In view of these conflicting findings, an integrated approach that reconciles the two theories has emerged (408).”
BackgroundMicko, A. S. G., Wöhrer, A., Wolfsberger, S., & Knosp, E. (2015) · Journal of Neurosurgery · doi:10.3171/2014.12.jns141083 · Cited by 577
Mechanisms for pituitary tumorigenesis: the plastic pituitary
Melmed, S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320401 · Cited by 456
A Pituitary-Derived MEG3 Isoform Functions as a Growth Suppressor in Tumor Cells
Zhang, X., Zhou, Y., Mehta, K. R., Danila, D. C., Scolavino, S., Johnson, S. R., & Klibanski, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030222 · Cited by 435
Metadata
- Authors
- Asa, S. L., & Ezzat, S.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 1998-12-01
- Volume
- 19
- Issue
- 6
- Pages
- 798-827
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W1963747253
- Cited by
- 388
- References
- 222
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.